All Outputs (8)

Real‐world persistence of multiple sclerosis disease‐modifying therapies (2024)
Journal Article

Background and purpose: Treatment persistence is the continuation of therapy over time. It reflects a combination of treatment efficacy and tolerability. We aimed to describe real‐world rates of persistence on disease‐modifying therapies (DMTs) for p... Read More about Real‐world persistence of multiple sclerosis disease‐modifying therapies.

The Impact of COVID-19 on the Employment of People With Multiple Sclerosis: A Multi-Methods Study (2024)
Journal Article

Background: The COVID-19 pandemic led to approximately half of the working population in the United Kingdom being unable to work temporarily. This study aims to understand the employment needs and experiences of people with multiple sclerosis (MS) in... Read More about The Impact of COVID-19 on the Employment of People With Multiple Sclerosis: A Multi-Methods Study.

Risk of COVID-19 in people with multiple sclerosis who are seronegative following vaccination (2023)
Journal Article

Background: People with multiple sclerosis (pwMS) treated with certain disease-modifying therapies (DMTs) have attenuated IgG response following COVID-19 vaccination; however, the clinical consequences remain unclear. Objective: To report CO... Read More about Risk of COVID-19 in people with multiple sclerosis who are seronegative following vaccination.

Real-world annualized relapse rates from contemporary multiple sclerosis clinics in the UK: a retrospective multicentre cohort study (2023)
Journal Article

Background: Annualized relapse rate (ARR) is used as an outcome measure in multiple sclerosis (MS) clinical trials. Previous studies demonstrated that ARR has reduced in placebo groups between 1990 and 2012. This study aimed to estimate real-world AR... Read More about Real-world annualized relapse rates from contemporary multiple sclerosis clinics in the UK: a retrospective multicentre cohort study.

ADAMS project: a genetic Association study in individuals from Diverse Ancestral backgrounds with Multiple Sclerosis based in the UK. (2023)
Journal Article

Purpose Genetic studies of multiple sclerosis (MS) susceptibility and severity have focused on populations of European ancestry. Studying MS genetics in other ancestral groups is necessary to determine the generalisability of these findings. The gene... Read More about ADAMS project: a genetic Association study in individuals from Diverse Ancestral backgrounds with Multiple Sclerosis based in the UK..

An update on the use of sphingosine 1-phosphate receptor modulators for the treatment of relapsing multiple sclerosis (2023)
Journal Article

Multiple sclerosis (MS) is an immune-mediated disorder of the CNS manifested by recurrent attacks of neurological symptoms (related to focal inflammation) and gradual disability accrual (related to progressive neurodegeneration and neuroinflammation)... Read More about An update on the use of sphingosine 1-phosphate receptor modulators for the treatment of relapsing multiple sclerosis.

Developing a Patient Care Pathway for Emotional Support around the point of Multiple Sclerosis diagnosis: A Stakeholder Engagement Study (2023)
Journal Article

Background: Diagnosing multiple sclerosis (MS) can be a lengthy process, which can impact psychological wellbeing, condition management, and future engagement with health services. Therefore, providing timely and appropriate emotional support may imp... Read More about Developing a Patient Care Pathway for Emotional Support around the point of Multiple Sclerosis diagnosis: A Stakeholder Engagement Study.

Self-diagnosed COVID-19 in people with multiple sclerosis: a community-based cohort of the UK MS Register (2020)
Journal Article